Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25605834 | 1.00 | HRH3 (0.40) | HRH3KDM4ECYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL25029687 | 0.90 | NPC1 (0.40) | HRH3KDM4ECYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL24838147 | 0.87 | HRH3 (0.41) | HRH3KDM4ECYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL25631005 | 0.86 | KDM4E (0.52) | KDM4ECYP2C9CYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL25631004 | 0.86 | KDM4E (0.52) | KDM4ECYP2C9CYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL25600556 | 0.83 | CNR1 (0.34) | HRH3KDM4ECYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL25600554 | 0.83 | CNR1 (0.34) | HRH3KDM4ECYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL26202563 | 0.81 | NPC1 (0.45) | KDM4ECYP2C9CYP2C19KMT2ANPC1 | |
| SCHEMBL25030889 | 0.79 | NPC1 (0.43) | KDM4ECYP2C9CYP2C19KMT2ANPC1 | |
| SCHEMBL25631007 | 0.79 | OPRL1 (0.38) | KDM4ECYP2C9CYP2C19ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | HRH3 3548/4885KDM4E 223/4885CYP2C9 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.